Download PDF

Interstitial Cystitis/Bladder Pain Syndrome¶

Chapter 54 | Part 2: Cardinal Manifestations and Presentation of Diseases · Part 2 – Cardinal Manifestations & Presentation · Chapter 54

Key Clinical Points¶

IC/BPS is a diagnosis of exclusion characterized by chronic bladder/pelvic pain (>6 weeks) associated with lower urinary tract symptoms (LUTS) in the absence of infection or other identifiable causes.
Clinical heterogeneity leads to distinct phenotypes: 'Pelvic Pain Only' (20-25%), 'Widespread Pain' (associated with COPCs like IBS, fibromyalgia), and 'Hunner Lesions'.
Diagnosis requires ruling out UTI (via culture), bladder cancer (via cytology), and other pathologies; cystoscopy is recommended for phenotyping (Hunner lesions vs. glomerulations).
Management is multimodal and phenotype-directed: universal conservative measures (education, diet, pelvic floor PT) are first-line.
Specific treatments include gabapentinoids/antidepressants for widespread pain and local injections or surgery for Hunner lesions.
Pelvic floor dysfunction is common (40-60%); pelvic floor physiotherapy is supported by level 1 evidence for this phenotype.
Recurrent UTIs can trigger symptom flares; UTI vaccination is considered for patients with recurrent infections.
IC/BPS is frequently associated with chronic overlapping pain conditions (COPCs) such as fibromyalgia, IBS, and chronic fatigue syndrome (CFS).

DEFINITION & OVERVIEW¶

• Core Definition:

Definition (Harrison's 22e): an unpleasant sensation (pain, pressure, discomfort) perceived to be related to the urinary bladder, associated with LUTS of >6 weeks' duration, in the absence of infection or other identifiable plans. • Clinical Context: ◦ Chronic Nature: Symptoms must persist for >6 weeks. ◦ Symptom Scope: Includes pain perceived as bladder-related and lower urinary tract symptoms (LUTS). ◦ Extra-bladder Pain: Pain in the pelvis, perineum, genitals, and abdomen is common. • UCPPS Classification: ◦ General term: Urologic chronic pelvic pain syndrome (UCPPS). ◦ Components: Includes IC/BPS (men and women) and CP/CPPS (men only). ◦ Distinction: CP/CPPS involves pain localized to the perineum and/or male genitals; IC/BPS can exist independently of CP/CPPS in men.

Historical Context & Nomenclature¶

• 1887: First description of the condition. • Hunner Lesions: The term for bladder-wall ulcerations (formerly known as 'classic' bladder-wall ulcerations). • 1998 NIDDK Consensus: Initial definition based on cystoscopic findings (glomerulations or Hunner lesions). • Evolution: Shifted toward IC/BPS to reflect the clinical syndrome of pain with LUTS and negative cultures.

EPIDEMIOLOGY¶

• Prevalence (Women): ◦ Estimated at 2.7–6.5% of North American women. ◦ Note: Fewer than 10% of symptomatic women receive a formal IC/BPS diagnosis. • Gender Distribution: ◦ Reported 10:1 female-to-male ratio; significantly underreported in men. • Risk Factors & Predictors: ◦ Childhood factors: UTI, bowel/bladder dysfunction, or sexual trauma. ◦ Chronic Overlapping Pain Conditions (COPCs): Fibromyalgia, IBS, chronic back pain, and chronic fatigue syndrome (CFS). • Co-morbidity Prevalence: ◦ >1/3 of patients have at least one COPC (IBS, fibromyalgia, or CFS). ◦ Up to 10% have multiple COPCs.

ETIOLOGY & PATHOPHYYSOLOGY¶

• General Concept: ◦ Not a single etiology; viewed as a syndrome of interrelated processes. • Microbial Theory: ◦ Infection is not the cause, but dysbiosis in the lower urinary tract may trigger flares. • Urothelial Dysfunction: ◦ GAG Layer: Potential breakdown of glycosaminoglycans or tight junctions allowing urine components to reach the bladder interstitium. ◦ APF: Antiproperiferative factor (slower growth of urothelial cells in IC/BPS patients). • Autoimmunity: ◦ High prevalence of B cell-mediated conditions (RA, SLE, Sjögren's) in these patients. ◦ Shared B cell clonotypes found in patients with Hunner lesions. • Pelvic Organ Crosstalk: ◦ Evidence of autonomic nervous system abnormalities and neural sensitization. • Neurobiologic & Central Sensitization: ◦ MAPP studies show structural/functional brain differences predicting symptom progression. ◦ QST findings: Generalized pain hypersensitivity and impaired endogenous inhibitory control. ◦ TLR Response: Women with higher TLR4 response show more severe symptoms, widespread pain, and more COPCs.

CLINICAL FEATURES¶

• Symptom Presentation: ◦ Primary complaint: Bladder pain (most distressing, impacts quality of life). ◦ Secondary complaints: LUTS (daytime/nighttime frequency and urgency). ◦ Behavioral impact: Patients void frequently to alleviate pain or due to fear of pain. • Pain Phenotypes: ◦ Pelvic Pain Only: 20–25% of patients; includes pelvic floor dysfunction and gynecologic pain. ◦ Widespread Pain: Associated with COPCs (IBS, fibromyalgia). ◦ Hunner Lesions: Identified via cystoscopy/hydrodistension; requires specific local treatment. • Pain Trajectories: ◦ Type 1: Gradual progression from mild discomfort → bladder filling pain → chronic unremitting pelvic pain. ◦ Type 2: Acute, UTI-like presentation (pain/urgency) that persists as a chronic cystitis-like syndrome. ◦ Type 3: Waxing and waning; flares triggered by diet, stress, infection, or menses. • Associated Conditions: ◦ Pelvic floor dysfunction (40–60%). ◦ Other COPCs: IBS, Fibromyalgia, CFS, chronic back pain.

Longitudinal Course¶

• 12-Month Follow-up Study: ◦ 60% stable. ◦ 20% improved. ◦ 20% worsened.

DIFFERENTIAL DIAGNOSIS¶

• Urinary Tract Infection (UTI): ◦ Must be ruled out via culture; common cause of flare. • Bladder Cancer: ◦ Rule out if hematuria is present or cytology is abnormal. • Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS): ◦ Key distinction in males; characterized by perineal/genital pain focus. • Other Pathologies: ◦ Diagnosis of exclusion requires ruling out other identifiable causes.

DIAGNOSTIC APPROACH¶

History and Physical Examination:
Conduct a pelvic exam (recommended), including evaluation of the pelvic floor.
Categorize symptoms as bladder/pelvis focused and/or extending beyond the pelvis.
Patient Education & Monitoring:
Begin with conservative measures.
Use frequency/volume charts to provide objective evidence of LUTS.
Laboratory Testing (Rule out other pathology):
Urinalysis and Culture (to rule out UTI).
Urine Cytology (if hematuria or cancer suspected).
Specialized Procedures:
Cystoscopy: Essential for phenotyping (identifying Hun1ner lesions) and ruling out other pathologies.
Hydrodistension: Used to assess bladder response.
Screening for Comorbidities:
Screen for COPCs (IBS, fibromyalgia, CFS, back pain, headache).

Investigation Recommendations¶

• Mandatory: History, Physical examination (including pelvic exam and evaluation of the pelvic floor). • Recommended: Frequency/volume chart, Urinalysis, Urine culture, Symptom scores, Cystoscopy, Hydrodistension. • Optional: Ultrasound/pelvic imaging, Postvoid residual, Urine cytology, Intravesical anesthetic bladder challenge.

MANAGEMENT & TREATMENT¶

Universal Baseline Management:
Education.
Diet modifications.
Exercise (including pelvic floor physical therapy).
Counseling/Psychosocial support.
Phenotype-Specific Interventions:
Pelvic Floor Dysfunction → Physical therapy, Trigger point injections, Acupuncture, Massage.
Pelvic Pain Only → Bladder distension, Diet modifications, Internal therapy, Sacral nerve stimulation, Hydrodistension, Botulinum toxin, Radical surgery.
Widespread Pain → Gabapentinoids, Amitriptyline, Hydroxyzine, Antidepressants, Sacral nerve neurostimulation.
Hunner Lesions → Cyclosporine, Injection of HLs, Steroid injection of HLs, Radical surgery.
Infection Management:
Antibiotics for acute flares.
Conservative UTI vaccination for patients with recurrent UTIs.
Psychosocial Support:
Stress management, Mindfulness, Cognitive behavioral therapy (CBT), Psychological support.

Flowchart: Management Paradigm¶

Initial Diagnosis: IC/BPS identified.
Universal Treatment Path:
Education → Diet → Exercise → Counseling.
Phenotype Stratification (Decision Node):
Based on: Clinical phenotype, Impact on quality of life, Severity of symptoms, Patient preference.
Branching Pathways:
If Pelvic Floor Dysfunction:
Physical therapy → Trigger point injections → Acupuncture → Massage.
If Pelvic Pain Only:
Bladder distension → Diet modifications → Internal therapy → Sacral nerve stimulation → Hydrodistension → Botulinum toxin → Radical surgery.
If Widespread Pain:
Gabapentinoids → Amitriptyline → Hydroxyzine → Antidepressants → Sacral nerve neurostimulation.
If Hunner Lesions:
Cyclosporine → Injection of HLs → Steroid injection of HLs → Radical surgery.
If Associated Infection:
Antibiotics → Conservative UTI vaccination (for recurrent cases).
If Psychosocial focus:
Stress management → Mindfulness → Cognitive behavioral therapy → Psychological support.

PROGNOSIS & COMPLICATIONS¶

• Longitudinal Course: ◦ 60% of patients remain stable over a 12-month period. • Impact on Quality of Life: ◦ Significant impact due to combination of bladder pain and urinary frequency.

SPECIAL CONSIDERATIONS¶

• Infection Management: ◦ Patients are at equal risk for UTIs as the general population. ◦ Rule out infection first; treat with antibiotics if flare is suspected to be infectious. • Male Population: ◦ Diagnosis of IC/BPS must be distinguished from CP/CPPS. ◦ Assessment should include wider pain locations outside the pelvis.

KEY PEARLS & CLINICAL TRAPS¶

• Diagnosis of Exclusion: Always rule out UTI and bladder cancer first. • Phenotype Matters: Treatment changes significantly based on whether the patient has Hunner lesions (local treatment) vs. widespread pain (systemic/neuromodulators). • Pelvic Floor Role: 40-60% have pelvic floor dysfunction; PT is a high-evidence intervention for this group. • Cystoscopy Utility: Not just for ruling out cancer, but for identifying Hunner lesions to guide specific injection therapies.

Reference Tables¶

TABLE 54-1 Workup of Patients by a Primary Care Practitioner or General Internist¶

Harrison's 22e, p.332

STEPS IN WORKUP	SPECIFICS
History/physical examination	Conduct a pelvic exam (recommended), including evaluation of the pelvic floor. Categorize symptoms as bladder/pelvis focused and/or extending beyond the pelvis.
Consideration of patient- centered treatment options if satisfied with diagnosisa	Begin with conservative measures. Introduce further symptom-specific treatments as needed.

TABLE 54-2 Recommendations for Investigations in Patients with Suspected Interstitial Cystitis/Bladder Pain Syndrome…¶

Harrison's 22e, p.333

MANDATORY	RECOMMENDED	OPTIONAL	NOT RECOMMENDED
History	Frequency/volume chart	Ultrasound/pelvic imaging	Potassium sensitivity test
	Urinalysis	Postvoid residual
	Urine culture	Urine cytology
	Symptom scores	Intravesical anesthetic bladder challenge
	Cystoscopy	Hydrodistension